In this study using a cirrhotic NASH model with PH, the non-steroidal FXR agonist cilofexor presented significant anti-fibrotic effects and ameliorated PH when administered alone or in combination with propranolol. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.